Earlier this month Phase II of a clinical trial relating to mesothelioma treatment. The aim of the study is to assess the effectiveness of an antibody in terms of slowing the growth of a protein that is found in excessive levels in tumors that are seen in mesothelioma patients. The protein is called mesothelin.

The Phase II trial has been initiated by a biopharmaceutical company, Morphotek Inc. The company is a subsidiary of Eisai Corporation of North America. The trial into its MORAb-009 monoclonal antibody will assess the effects of the drug when combined with the chemotherapy drugs pemetrexed and cisplatin.

The treatment is aimed at seeing whether patients with advanced malignant pleural mesothelioma can continue survival without further progression of the disease as a result of the treatment. Nearly ninety participants were to take part in the trail, including those that had been diagnosed but had not yet received treatment.

As the trial began Chief Medical Officer of Morphotek Martin D. Phillips, M.D. stated: “We are excited to have initiated this Phase II study of MORAb-009 in mesothelioma in cooperation with leading physician-scientists.”

Be Sociable, Share!